Welcoming a New Leader to Hemanext
Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, is excited to introduce Mr. Shane Ray as their new Chief Commercial Officer (CCO). In this critical role, Shane will spearhead the global commercial strategy and execution for Hemanext ONE.
Shane Ray's Expertise and Experience
Shane brings over 20 years of global leadership experience in the medical technology industry, with a remarkable record in commercialization, strategic marketing, and business development. His prior role as North American President and Global Chief Marketing Officer at curasan, Inc. allowed him to refine his skills within high-growth medical device companies focused on regenerative medicine.
Throughout his career, Shane has held senior leadership positions at RTI Surgical and Pioneer Surgical Technology, where he successfully directed sales and marketing efforts across various sectors such as orthobiologics and sports medicine. This diverse experience positions him well to lead Hemanext towards significant achievements.
A Vision for Growth
Andrew Dunham, CEO of Hemanext, expressed his enthusiasm stating, “We are thrilled to welcome Shane Ray as our new Chief Commercial Officer. His proven leadership and strategic vision will be pivotal as we accelerate our commercial growth and deepen our customer impact.” With a clear focus on advancing patient outcomes and ensuring sustainable commercial success, Shane's guidance is expected to create lasting value for the company.
Shane's Commitment to Innovation
“I am honored and thrilled to join the Hemanext team,” said Shane Ray, CCO of Hemanext. “Hemanext is pioneering innovative blood therapies, and I look forward to building on the company’s strong foundation to advance patient outcomes while driving sustainable commercial success.” Shane’s commitment to innovation aligns perfectly with Hemanext's mission to improve the quality, safety, and cost of transfusion therapy.
About Hemanext
Hemanext is dedicated to advancing transfusion therapy through innovative technologies. This privately-held company invests in research that focuses on hypoxically stored red blood cells (RBCs), aiming to enhance the quality of stored RBCs globally.
Hemanext ONE: Pioneering Technology
HEMANEXT ONE is the company's flagship device developed to enhance the quality of RBCs for transfusion-dependent patients. This first-of-its-kind device has received marketing authorization for commercial distribution via the De Novo process from the U.S. Food & Drug Administration. Additionally, HEMANEXT ONE is CE marked in Europe, enabling it to be distributed within the European Economic Area (EEA).
Contact Information
Individuals or organizations interested in learning more about Hemanext and its innovative solutions can reach out directly. Below are the contact details:
Hemanext
Robert Haime, Vice President, Commercial
(781) 301-7474
Contact via Email
Website: Hemanext.com
Frequently Asked Questions
What position has Shane Ray been appointed to at Hemanext?
Shane Ray has been appointed as the Chief Commercial Officer (CCO) of Hemanext.
What experience does Shane Ray bring to Hemanext?
With over 20 years in the med-tech industry, Shane has a strong background in commercialization, strategic marketing, and business development.
What is Hemanext primarily focused on?
Hemanext focuses on improving the quality, safety, efficacy, and cost of transfusion therapy through innovative medical technology.
What is HEMANEXT ONE?
HEMANEXT ONE is an innovative device designed to enhance the quality of red blood cells for patients requiring transfusions.
How can I contact Hemanext for more information?
You can contact Hemanext directly via their website at Hemanext.com or by reaching out to their Vice President, Robert Haime, at (781) 301-7474.
